Policy & Regulation
Adicet Presents Preclinical Data Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies
10 May 2022 - - US-based clinical stage biotechnology company Adicet Bio, Inc. (NASDAQ: ACET) has presented data from a preclinical evaluation of ADI-001 at the International Society for Cell and Gene Therapy annual meeting taking place in San Francisco, May 4-7, 2022, the company said.

ADI-001 is currently being evaluated in an ongoing dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin's lymphoma.

The preclinical evaluation reported at ISCT observed that ADI-001 exhibited a predominantly naïve-like T cell memory phenotype, expressed multiple chemokine and innate-activating cell receptors and exhibited robust in vitro and in vivo tumor growth inhibition against multiple human lymphoma cell lines, with adaptive and innate activation pathways contributing to the anti-tumor activity of ADI-001.

Susceptibility to host versus graft targeting was also evaluated using mixed-lymphocyte reactions incorporating up to 13 different allogeneic lymphocyte samples.

Non-gene-edited ADI-001 gamma delta CAR T cells demonstrated high levels of endogenous HLA-E expression in the unmodified state and were associated with superior resilience to lymphocyte-mediated clearance when compared to approaches commonly deployed in gene-edited allogeneic cell therapy platforms (β2MKO with or without HLA-E overexpression).

Adicet Bio is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer.

Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.


Related Headlines